

Special Issue

Hybrid and Chimeric Heterocycles: A Promising Approach to Synthesizing Biologically Active Compounds

Message from the Guest Editor

A literature survey revealed that heterocycles are privileged core scaffolds in medicinal chemistry, playing an essential role in drug design and reported to exhibit many biological and pharmacological activities, including antimicrobial, antiviral, anthelmintic, anti-HIV, anticancer, antiallergic, diuretics, cardiotonics, antihypertensive, antiplatelet, analgesic, anxiolytic, antidepressant, hypnotic sedative, antineurodegenerative, anti-Alzheimer's, etc. One of the most promising approaches used by scientists in the design of new drugs is the Multiple Targeting Drugs (MTD) approach. Usually drug candidates in the Multiple Targeting Drugs approach are classified as Hybrid Drugs (HDs) or Chimeric Drugs (CDs). This Special Issue aims to present the latest developments in biologically active compounds with a hybrid and/or chimeric heterocyclic core, with a focus on the synthesis, structure and biological activity of these compounds.

Guest Editor

Prof. Dr. Ionel Mangalagiu

Chemistry Department, Alexandru Ioan Cuza University of Iasi, 700506 Iasi, Romania

Deadline for manuscript submissions

25 December 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/239678

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)